Recursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall Progress

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Nasdaq

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...
Nasdaq

First Week of November 21st Options Trading For Recursion Pharmaceuticals

Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
The Motley Fool

If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
来自MSN

Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...
来自MSN

Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, Needham retained its Buy rating on Recursion Pharmaceuticals, ...